LOC441150 Inhibitors
Chemical inhibitors of LOC441150 function by targeting various signaling pathways and cellular processes that are essential for the protein's activity within the cell. Palbociclib, Ribociclib, and Abemaciclib specifically inhibit cyclin-dependent kinases CDK4 and CDK6, which are crucial regulators of the cell cycle. These kinases facilitate the transition from the G1 phase to the S phase, a critical step for DNA replication and cell division. By inhibiting CDK4 and CDK6, these chemical inhibitors can arrest cells in the G1 phase, thereby preventing the progression of the cell cycle where LOC441150 is active. This inhibition can lead to a reduction in cell proliferation, effectively diminishing the function of LOC441150 by halting the cellular processes that allow it to operate.
On the other hand, chemical inhibitors targeting the PI3K/mTOR signaling pathway, such as Omipalisib, AZD8055, Torin 1, Buparlisib, Dactolisib, LY294002, Wortmannin, Rapamycin, and AZD2014, interfere with cellular growth and survival mechanisms. The PI3K/mTOR pathway plays a pivotal role in translating extracellular signals into cellular responses, including protein synthesis, growth, and survival. Inhibitors like Omipalisib and AZD8055 selectively impede mTOR kinase, which is a central component of this pathway. Torin 1's inhibition of mTOR leads to autophagy and apoptosis, processes that degrade cellular components and induce cell death. Buparlisib and LY294002 are potent PI3K inhibitors, while Dactolisib and Wortmannin also block PI3K, leading to decreased AKT phosphorylation. The inhibition of PI3K and mTOR by these compounds results in a disruption of the downstream effects, such as reduced protein synthesis and suppressed cell growth, thereby functionally inhibiting LOC441150 by limiting the cellular resources and signaling required for its function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib selectively inhibits cyclin-dependent kinases CDK4 and CDK6. As CDK4/6 are involved in cell cycle regulation, their inhibition can lead to reduced proliferation of cells expressing LOC441150, thereby functionally inhibiting the protein by preventing cell cycle progression. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Similar to Palbociclib, Ribociclib targets CDK4 and CDK6, which are crucial for cell cycle G1-S transition. Its inhibition of these kinases can lead to decreased proliferation of cells where LOC441150 is active, resulting in functional inhibition of LOC441150 due to arrested cell growth. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is another CDK4 and CDK6 inhibitor, which can impede the cell cycle in the G1 phase. By doing so, it can functionally inhibit LOC441150 by halting cell division and proliferation where LOC441150 is implicated. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $260.00 $1029.00 | ||
Omipalisib inhibits PI3K/mTOR signaling pathway. The PI3K/mTOR pathway is involved in cellular growth and survival. Inhibition of this pathway can lead to decreased cellular activities where LOC441150 is involved, thus functionally inhibiting LOC441150. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1 is an mTOR inhibitor that can lead to autophagy and apoptosis. Its action can reduce cellular survival and proliferation, thus functionally inhibiting LOC441150 by promoting the degradation of cellular components including LOC441150. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $173.00 $230.00 $275.00 $332.00 | 9 | |
Buparlisib is a pan-class I PI3K inhibitor. By inhibiting PI3K, it can lead to reduced activation of downstream targets, including AKT and mTOR, thereby functionally inhibiting LOC441150 through decreased cell survival signaling. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
Dactolisib, also known as NVP-BEZ235, is a dual PI3K and mTOR inhibitor. It can functionally inhibit LOC441150 by blocking the PI3K/AKT/mTOR signaling pathway, which is essential for cell growth and survival. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a chemical inhibitor of PI3K. By inhibiting PI3K, LY294002 can decrease AKT phosphorylation and activation, leading to functional inhibition of LOC441150 by impeding the signaling pathway it is associated with. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. Inhibition of PI3K can lead to a reduction in AKT signaling, effectively leading to functional inhibition of LOC441150 by hindering the pathway necessary for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTORC1, which can result in decreased protein synthesis and cell growth. By inhibiting mTORC1, Rapamycin can functionally inhibit LOC441150 by reducing the cellular capability for protein expression and proliferation. | ||||||